Evidence map›Paper›PMID 29721200›Full record

ArticleOncotarget2018

Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, Qinghong Han, Yuying Tan, Emily Gainor, Tasuku Kiyuna, Kentaro Miyake, Masuyo Miyake, Takashi Higuchi and 14 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Kentaro IgarashiAntiCancer, Inc., San Diego, California, USA.
Kei KawaguchiAntiCancer, Inc., San Diego, California, USA.
Shukuan LiAntiCancer, Inc., San Diego, California, USA.
Qinghong HanAntiCancer, Inc., San Diego, California, USA.
Yuying TanAntiCancer, Inc., San Diego, California, USA.
Emily GainorAntiCancer, Inc., San Diego, California, USA.
Tasuku KiyunaAntiCancer, Inc., San Diego, California, USA.
Kentaro MiyakeAntiCancer, Inc., San Diego, California, USA.
Masuyo MiyakeAntiCancer, Inc., San Diego, California, USA.
Takashi HiguchiAntiCancer, Inc., San Diego, California, USA.
Hiromichi OshiroAntiCancer, Inc., San Diego, California, USA.
Arun S SinghDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Mark A EckardtDepartment of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Scott D NelsonDepartment of Pathology, University of California, Los Angeles, CA, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Sarah M DryDepartment of Pathology, University of California, Los Angeles, CA, USA.
Yunfeng LiDepartment of Pathology, University of California, Los Angeles, CA, USA.
Norio YamamotoDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Katsuhiro HayashiDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Hiroaki KimuraDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Shinji MiwaDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Hiroyuki TsuchiyaDepartment of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Robert M HoffmanAntiCancer, Inc., San Diego, California, USA.
AntiCancer (United States) · USKanazawa University · JPUniversity of California, Los Angeles · USUniversity of California, San Diego · USYale University · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

Synovial sarcoma (SS) is a recalcitrant subgroup of soft tissue sarcoma (STS). A tumor from a patient with high grade SS from a lower extremity was grown orthotopically in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) mouse model. The PDOX mice were randomized into the following groups when tumor volume reached approximately 100 mm

Indexed as

doxorubicinpatient-derived orthotopic xenograftPDOXrecombinant methioninasesynovial sarcoma

Identifiers

PMID29721200
PMCPMC5922394
OpenAlexW2796729556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.